Global Dyspnea Treatment Market, by Treatment (Therapy (Supplemental Oxygen Therapy, Relaxation Therapy), Drugs (Antianxiety Drugs, Antibiotics, Anticholinergic Agents, Corticosteroids)), By Route of Administration (Oral, Inhalation), By End-User (Hospitals, Home Care, Specialty Centers, Other End-Users), and by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

Dyspnea Treatment Market Overview:

The global dyspnea treatment market is projected to increase at a CAGR of 5.45%, between 2022 to 2032.

Dyspnea, defined as a feeling of breathlessness, is a common symptom of many different diseases and disorders. Dyspnea is a symptom that should not be ignored and can be treated with medication and other treatment options. It can be caused by respiratory problems, such as asthma or Chronic Obstructive Pulmonary Disease (COPD), or from certain heart conditions. All of these factors result in the lungs not carrying enough oxygen to the body’s cells. Other causes could be something as simple as anemia due to lack of iron. It can be treated with medication such as bronchodilators and inhaled corticosteroids, along with other therapies such as oxygen, nebulizer treatments, and chest physiotherapy. Supplemental oxygen therapy should only be used when the patient has trouble breathing even though they are receiving sufficient oxygen. The patient’s physician should be informed before giving supplemental oxygen.

Most cases of dyspnea are not life-threatening. Breathing problems can be either acute or chronic. Acute breathing problems include bronchitis, asthma, pneumonia, and viral infections. Chronic breathing disorders are often the result of emphysema, COPD, and heart disease. These disorders cause the lungs to become less elastic and constrict over time, which decreases airflow into the lungs.

Global Dyspnea Treatment Market Revenue (US$ Mn), 2021–2031:

There are a number of drivers that can be attributed to the rapid revenue growth of this global industry. One is a better understanding on the part of general physicians and medical professionals of the condition. The other is an increase in people suffering from chronic respiratory diseases such as asthma, cystic fibrosis, COPD, or pneumonia.

Dyspnea is a sensation of labored breathing or shortness of breath and is one of the most common symptoms for people with lung diseases such as COPD. Treatment options for dyspnea include pulmonary rehabilitation, oxygen therapy, and inhaled bronchodilators, all of which are costly and inconvenient forms of treatment that require frequent doctor consultations.

Revenue growth restraints for the global dyspnea treatment market are primarily, the availability of low-cost generic medicines, a lack of marketing spending on the part of manufacturers, the high cost of marketing prescription therapies, as well as low patent protection for brand name products.
Increased spending on healthcare infrastructure development, a surge in the prevalence of indoor and outdoor pollutants, as well as an increase in strategic collaborations among market participants, are factors fueling this market’s economic growth. Increasing personal disposable incomes, in conjunction with surging levels of unmet demands for the treatment of this condition are other variables that could potentially impact the projected revenue trajectory of this market.

Dyspnea is such a common symptom that it generally goes undiagnosed among individuals who seek medical help. As global populations age, the prevalence of chronic lung disease and other respiratory diseases will inevitably increase, subsequently leading to a greater need for appropriate treatment. In the United States alone, as many as 25 million people suffer from dyspnea at some point in their lives. For the past 10 years, the global dyspnea treatment market has had a slow but steady rate of growth. On account of climate change and global warming, this market is expected to index rapid economic growth in years to come. In order to remain sustainable and viable, new technologies are being developed for those that are plagued by this disorder.

In February 2019, the Therapeutic Goods Administration (TGA) in Australia granted Mayne Pharma Group Limited approval for Kapanol (morphine sulphate pentahydrate), a low-dose sustained-release morphine capsule for the treatment of chronic dyspnea in palliative care patients with an advanced form of disease. The approval of Kapanol would help patients with severe COPD, heart failure, cancer, or other causes of chronic shortness of breath in palliative care.

Key Players:

This research report on the global EV charging connector market includes major company profiles such as:

• Novartis AG
• Boehringer Ingelheim International GmbH
• Nephron Pharmaceuticals Corporation
• Cadila Healthcare Limited
• Mayne Pharma Group Limited
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc.
• Bausch Health Companies Inc.
• Ligand Pharmaceuticals Incorporated
• Ligand Pharmaceuticals Incorporateda
• Lupin Pharmaceuticals Inc.
• Others

The Global Dyspnea Treatment Market Segmentation is Based on Treatment, Route of Administration, End-User, and Region:

Based on Treatment

• Therapy
  • Supplemental Oxygen Therapy
  • Relaxation Therapy
• Drugs
  • Antianxiety Drugs
  • Antibiotics
  • Anticholinergic Agents
  • Corticosteroids

Based on Route of Administration

• Oral
• Inhalation

Based on End-User

• Hospitals
• Home Care
• Specialty Centers
• Other End-Users

Based on Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

For the Dyspnea Treatment Market research study, the following years have been considered to estimate the market size: